Literature DB >> 22479270

Allogeneic stem cell transplantation for neuroblastoma.

Ki Woong Sung1.   

Abstract

Entities:  

Year:  2012        PMID： 22479270      PMCID： PMC3317468          DOI： 10.5045/kjh.2012.47.1.3

Source DB:  PubMed          Journal:  Korean J Hematol        ISSN： 1738-7949


× No keyword cloud information.
  9 in total

1.  Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial.

Authors:  C Jubert; D A Wall; M Grimley; M A Champagne; M Duval
Journal:  Bone Marrow Transplant       Date:  2010-05-03       Impact factor: 5.483

2.  Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma.

Authors:  Hiroka Takahashi; Atsushi Manabe; Chiaki Aoyama; Takahiro Kamiya; Itaru Kato; Ayako Takusagawa; Chitose Ogawa; Miwa Ozawa; Ryota Hosoya; Kunihiko Yokoyama
Journal:  Pediatr Blood Cancer       Date:  2008-03       Impact factor: 3.167

3.  Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation.

Authors:  Ki Woong Sung; Jun Eun Park; Hee Won Chueh; Soo Hyun Lee; Keon Hee Yoo; Hong Hoe Koo; Ju Youn Kim; Eun Joo Cho
Journal:  Pediatr Blood Cancer       Date:  2011-06-16       Impact factor: 3.167

4.  High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.

Authors:  Jacek Toporski; Michael Garkavij; Jan Tennvall; Ingrid Ora; Katarina Sjögreen Gleisner; Josefina H Dykes; Stig Lenhoff; Gunnar Juliusson; Stefan Scheding; Dominik Turkiewicz; Albert N Békássy
Journal:  Biol Blood Marrow Transplant       Date:  2009-07-08       Impact factor: 5.742

5.  Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects.

Authors:  P Lang; M Pfeiffer; I Müller; M Schumm; M Ebinger; E Koscielniak; T Feuchtinger; J Föll; D Martin; R Handgretinger
Journal:  Klin Padiatr       Date:  2006 Nov-Dec       Impact factor: 1.349

6.  Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN.

Authors:  K Goi; T Inukai; H Honna; K Akahane; K Hirose; I Kuroda; N Hasuda; K Koshizuka; K Takano; K Sugita
Journal:  Bone Marrow Transplant       Date:  2010-08-09       Impact factor: 5.483

7.  KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.

Authors:  Antonio Pérez-Martínez; Wing Leung; Evangelina Muñoz; Rekha Iyengar; Manuel Ramírez; José Luis Vicario; Alvaro Lassaletta; Julián Sevilla; Marta González-Vicent; Luis Madero; Miguel Angel Díaz-Pérez
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

8.  Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.

Authors:  Didier Blaise; Jacques Olivier Bay; Catherine Faucher; Mauricette Michallet; Jean-Michel Boiron; Bachra Choufi; Jean-Yves Cahn; Nicole Gratecos; Jean-Jacques Sotto; Sylvie François; Joel Fleury; Mohamad Mohty; Christian Chabannon; Karin Bilger; Gwenaelle Gravis; Frédéric Viret; Anne Chantal Braud; Valérie Jeanne Bardou; Dominique Maraninchi; Patrice Viens
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

9.  Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation.

Authors:  M Inoue; T Nakano; A Yoneda; M Nishikawa; M Nakayama; K Yumura-Yagi; N Sakata; M Yasui; T Okamura; K Kawa
Journal:  Bone Marrow Transplant       Date:  2003-07       Impact factor: 5.483
  9 in total
  1 in total

Review 1.  The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery.

Authors:  Caroline Hochheuser; Nina Y Kunze; Godelieve A M Tytgat; Carlijn Voermans; Ilse Timmerman
Journal:  J Pers Med       Date:  2021-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.